Tirzepatide is a novel synthetic peptide that functions as a dual agonist at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual-incretin mechanism distinguishes tirzepatide from single-receptor GLP-1 agonists, offering researchers a unique tool for investigating the complementary roles of GIP and GLP-1 signalling pathways in metabolic regulation.
In preclinical and clinical research settings, tirzepatide has demonstrated significant effects on glycaemic control, insulin secretion, appetite regulation, and adipose tissue metabolism. Its dual receptor activity is believed to produce synergistic improvements in insulin sensitivity beyond those observed with GLP-1 agonism alone, making it a highly relevant compound for obesity and type 2 diabetes research models.
Each vial contains 5mg of tirzepatide supplied as a lyophilised powder with a purity of >98% as verified by HPLC analysis.
Recommended storage is at -20°C in a dry environment, protected from light. Once reconstituted, solutions should be stored at 4°C and used within 14 days.
Molecular Formula
C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight
4813.5 g/mol
Purity
>98%
CAS Number
2023788-19-2
Form
Lyophilised Powder
Research Applications
Metabolic disease research, GLP-1 receptor signalling, GIP receptor signalling, insulin sensitivity studies, obesity and adiposity research, glycaemic regulation
For research purposes only. Not for human use. This product is intended solely for in vitro and preclinical research applications by qualified professionals.
Reviews
There are no reviews yet.